Kornimate/medical-research-clean huggingface dataset:
supra inguinal fascia iliaca block as rescue analgesia following total hip arthroplasty

Conditions: Hip Arthroplasty, Total; Post Operative Pain, Acute; Nerve Block

Summary: hip replacement surgery is one of the most commonly performed surgical procedures in france, with approximately 150,000 procedures per year. postoperative recovery has significantly improved in recent years, enabling faster rehabilitation. although generally considered moderately painful, hip replacement surgery can, in some difficult-to-predict cases, lead to severe postoperative pain, requiring high doses of morphine, which may cause side effects and delay recovery. in other surgical procedures, regional anesthesia (nerve blocks) has been successfully used for pain relief. however, its effectiveness after hip replacement surgery has not yet been fully proven. a recent regional anesthesia technique-the supra-inguinal fascia iliaca block (sifib)-which numbs a significant portion of the nerves around the hip, has recently been developed. when performed in all patients undergoing hip arthroplasty, the benefit of this technique could not be demonstrated. in addition, this technique may lead to transcient muscle blockade, wich also can delay recovery. in order to limit the use of nerve blocks to painful patients, we designed this study where the nerve block is performed only in patients experiencing significant paint after surgery. in conclusion, this study aims to assess the benefits of performing a rescue sifib in the recovery room for patients who experience significant postoperative pain after hip replacement surgery. the evaluation will focus on pain relief and ability to walk. no new treatment is being tested. the technique uses a commonly administered local anesthetic to numb the nerves.


Eligibility criteria:
inclusion criteria: * patient scheduled for a primary total hip arthroplasty under general anesthesia, * written informed consent. exclusion criteria: * per-operative complication making wheight-bearing and walking contra-indicated. * patient without significant pain post-operatively.

Keywords: total hip arthroplasty regional anesthesia nerve blocks supra-inguinal fascia iliaca block enhanced recovery after surgery acute post-operative pain rescue analgesia
community-effectiveness of the distribution of insecticide-treated bed nets through social marketing antenatal care services in malaria control in rural burkina faso

Conditions: Malaria

Summary: the study aims at assessing which of two distribution channels for insecticide treated bendnets (itns), social marketing vs. social marketing coupled with free distribution through ante-natal care, is most effective in reaching groups at high risk of malaria, i.e. pregnant women and children under 5.

the hypothesis that insecticide-treated bed net (itn) effects may not be long-lasting in young children living in areas of intense malaria transmission due to interactions with the immunologi-cal development has now been refuted in a number of studies including the d4 study. the highly controversial question remains how african programmes can best reach a sustainable high coverage with itns in young children and pregnant women. against this background it is planned to implement a cluster randomised controlled trial in nouna health district in burkina faso. twenty-two peripheral health centres and their catchment areas will be randomised to (1) itn provision to the general population through social marketing and (2) itn provision to the general population through social marketing plus free provision to all pregnant women through antenatal services. the primary outcomes are itn coverage in households and itn use during pregnancy and infancy.

Eligibility criteria:
inclusion criteria: * being one of 25 primary health facility catchment areas in the nouna health district, burkina faso exclusion criteria: * being outside one of 25 primary health facility catchment areas in the nouna health district, burkina faso

Keywords: insecticide-treated bednets malaria africa social marketing ante-natal care itn coverage itn use
educational programs based on healthy habits to improve quality of life and psychosocial profile in women with neurodegenerative diseases: the advice protocol study (phase 1)

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting

Summary: this phase of the project aims to analyze the interaction between physical exercise and the phases of the menstrual cycle, evaluating its impact on fatigue, functional capacity, and exercise perception in women with and without multiple sclerosis. to achieve this, a controlled, single-blind, prospective, 2x3 crossover, randomized clinical trial will be conducted, involving women with multiple sclerosis (ms), matched by age, lifestyle habits (smoking, physical activity), and geographic location with a group of women without ms. this study, aligned with previous findings, seeks to deepen the understanding of the role of exercise in managing multiple sclerosis symptoms and to promote greater adherence to personalized physical activity programs adapted to the phases of the menstrual cycle.


Eligibility criteria:
inclusion criteria include: * women of reproductive age (18-50 years) with ms will be included, with the upper age limit adjusted to reflect the reproductive phase;. * no iron-deficiency anemia. * stable disease phase. * independent walking ability for over 10 meters. women will be recruited first and later matched with men based on age, edss, and lifestyle habits (physical activity, smoking, and alcohol consumption). exclusion criteria will include participants with ms who: * score \ 6 on the edss. * report a relapse within 12 months before the study begins. * have taken corticosteroid treatment within the last 2 months. * have participated in a structured training program in the previous 6 months. once all women with ms are recruited, male participants will be recruited following a 1:1 matching methodology based on age, geographic region, and lifestyle habits.

Keywords: lifestyle interventions menstrual cycle multiple sclerosis exercise cognitive-behavioral intervention physical activity, psychosocial well-being nutrition intervention
ngal predictive value of acute kidney failure after cardiac surgery in patients with preoperative chronic kidney failure

Conditions: Preoperative KIDNEY FAILURE, CHRONIC; Postoperative KIDNEY FAILURE, ACUTE; Cardiac Surgical Procedures

Summary: primary endpoint: to evaluate predictive value of plasmatic levels of neutrophil gelatinase associated lipocalin (ngal) to reveal acute kidney failure after cardiac surgery in patients with preoperative chronic kidney failure secondary endpoint is to obtain threshold values of ngal.

(n/a)

Eligibility criteria:
inclusion criteria: * renal clearance less than 60 ml/min * able to give written consent * elective valve surgery * elective cabg surgery exclusion criteria: * less than 18 years old * iodine injection within 3 days before surgery * iodine injection within 24 first postoperative hours * preoperative infection * evolutive cancer disease * refusal * pregnancy * unable to give written consent

Keywords: ngal plasmatic level preoperative kidney failure, chronic postoperative kidney failure, acute cardiac surgery procedures
immunological response after shrimp oral immunotherapy treatment

Conditions: Allergy to Shrimp; Immunotherapy

Summary: oral immunotherapy is effective in desensitized food allergy. shrimp allergy is increasing in thailand. so the purpose of our study is to determine level of specific immunoglobulin e antibodies to shrimp, immunoglobulin g4 and immunoblot analysis in shrimp allergy patients after shrimp oral immunotherapy.

all subject in this study were sensitized to shrimp. all patient was clinically evaluated, with focus on shrimp allergy by medical history, medical examination and gold standard oral food challenge test. compare oral immunotherapy to shrimp and shrimp avoidance. blood sample was taken for baseline determination of immunoglobulin e antibodies to shrimp. the primary outcome was the specific immunoglobulin e antibodies to shrimp,immunoglobulin g4 and immunoblot analysis in case that oral immunotherapy.

Eligibility criteria:
inclusion criteria: * age 12 - 40 years old * history of immunoglobulin e-mediated shrimp allergy \> 3 episode/year or disturb quality of life * positive oral food challenge test for shrimp exclusion criteria: * history of shrimp anaphylaxis (include cardiovascular or neurological symptoms) * shellfish dependent exercise induced anaphylaxis * history of cardiovascular disease, uncontrolled asthma, severe atopic dermatitis * history of beta-blocker, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker

Keywords: shrimp allergy oral immunotherapy specific immunoglobulin e skin sensitization
relation between withdrawal movement for rocuronium and emergence agitation

Conditions: Inguinal Hernia

Summary: rocuronium results in burning pain on injection site. it can be reduced by local anesthetics or opioid, but still some patients, especially in children, show withdrawal movement for pain. this might resulted from individual pain sensitivity. emergence agitation (ea) in children is quite frequent postoperatively and is known to be associated with postoperative pain. if a patient is susceptible to postoperative pain, he or she would have high probability of ea postoperatively. therefore, the investigators explore the relation of withdrawal movement of rocuronium and ea.


Eligibility criteria:
inclusion criteria: * asa class i, ii exclusion criteria: * intravenous cannulation other than a hand or an upper arm with 24 gauge catheter
an examination of predictors of indicators of response to celecoxib in women who have a diagnosis of early breast cancer

Conditions: Breast Cancer

Summary: to assess the quantitative real time pcr results results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors of indicators of response to celecoxib.

to assess the quantitative real time pcr results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to celecoxib, the feasibility of performing six different molecular assays by qrtpcr on formalin fixed paraffin embedded tissue obtained from breast cancer core biopsies and breast cancer reexcision patients, to assess change in ki-67, pcna, and several other markers by qrtpcr, correlate change in expression of ki-67, pcna, cax-2, and bcl-2, measured by immunohistochemistry to change measured by qrtpcr, and to determine the reliability of the qrtpcr and immunohistochemical assays by performed selected assays on the same tissue in two different institutions

Eligibility criteria:
inclusion criteria: * women with a recent diagnosis of t1 or t2 noninvasive breast cancer by large core needle or excisional biopsy * confirmation that tissue was processed in methods acceptable to protocol and sufficient tissue remains post diagnostic analyses to perform research assessments * reexcision planned within 10 days to 6 weeks from study start exclusion criteria: * no hormone replacement therapy within 90 days prior to biopsy * no history of asthma, allergy asa, nsaids, celecoxib of other cox-2 inhibitors for a chronic non-oncological condition with the excision of low dose asa (160 mg daily) during 4 weeks prior to biopsy and for the duration of the study * no celecoxib or rofecoxib use within one month of biopsy * no history of gastrointestinal ulcer or ulcerative colitis requiring treatment * no current anticoagulants * no neoadjuvant antihormone or chemotherapy as treatment following biopsy prior to study entry or concurrently with participation on study * no aromatase inhibitor in the six months prior to participation * no concomitant lithium * no known significant bleeding disorder

Keywords: breast atypia breast epithelial hyperplasia ki-67 rtpcr microdissection
to demonstrate the relative bioavailability of desipramine hydrochloride tablets

Conditions: Depression

Summary: to demonstrate the relative bioavailability of desipramine hydrochloride tablets.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: antidepressant
zn-ddc to target hypoxia-nfkappab-cscs pathway in multiple myeloma

Conditions: Multiple Myeloma

Summary: the outlook for patients with haematological malignancies remains challenging. it has been shown in some early cancer studies that a particular drug called zn-ddc otherwise known as imuthiol is highly toxic to cancer stem cells. imuthiol has been intravenously used in clinical trials with an excellent safety record. recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. this may lead to potential combination therapies which will be very effective as well as affordable in the future. there is the need to look to see if this drug, imuthiol and along with complementary drugs lenalidomide (revlimid) and pomalidomide (pomalyst) can help in haematological malignancy treatment. in order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. the success of this study may lead to quick translation of imuthiol into haematological malignancy treatment.

up to 60 myeloma bone marrow samples from myeloma patients and 10 bone marrow samples from other haematological malignancy samples (acute leukaemia's) at diagnosis and relapse will be tested. patients attending haematology clinics at new cross hospital will be reviewed for eligibility of the study by the clinician and if they meet the recruitment criteria, they will be approached to participate at clinic. after informed consent, participants will be asked to donate an additional 2-3ml sample of bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow aspirate as part of their routine clinical care at diagnosis and relapse.the single aliquot will be sent to the university of wolverhampton for analysis. specific clincial data will be collected at the time of diagnosis and relapse: * diagnosis * date diagnosed * disease stage * relapse status * age * sex * previous treatments * date of marrow sample * marrow trephine * marrow liquid the clinical data set will remain at the royal wolverhampton nhs trust whilst analysis of the samples takes place. once the samples have been analysed, the clinical data will then be released to determine relapsed or refractory disease and correlation with the in vitro data.

Eligibility criteria:
inclusion criteria: * patients diagnosed with haematological malignancy - either myeloma or acute leukaemia * patients must be 18 years or over * patients must be willing and able to give informed consent exclusion criteria: * pregnant patients will not be entered
comparative analysis of co2 monitoring methods in patients with cf undergoing general anesthesia

Conditions: Cystic Fibrosis

Summary: four methods are routinely used to monitor co2 in patients. end tidal co2 (etco2) is monitored through the endotracheal tube during general anesthesia. co2 is also monitored in other healthcare settings transcutaneously (tco2), via finger stick capillary co2 (capco2), and arterial blood gas (abg). the purpose of this study is to perform all four measurements simultaneously during general anesthesia to identify which measure provides the most accurate data with the least amount of patient risk.


Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of cystic fibrosis (positive sweat chloride value ≥ 60 meq/l) and/or genotype with two identifiable mutations consistent with cf, accompanied by one or more clinical features consistent with the cf phenotype) * hemodynamically stable undergoing general anesthesia for a scheduled procedure exclusion criteria: * patients not diagnosed with cf * cf patients undergoing anesthesia for emergency procedures
outcome measures of modified constraint induced movement therapy versus dual task training on upper extremity and cognitive functions in patients with hemiparesis

Conditions: Hemiparesis

Summary: all stroke patients were assessed via isokinetic dynamometer, montreal cognitive assessment scale (moca) and fugl myer upper extremity (fmue) before and after the treatment program.

the patients were classified randomly into three equal groups, study group a (ga) receiving modified constraint induced movement therapy in addition to conventional physical therapy program, study group b (gb) receiving dual task training in addition to conventional physical therapy program and control group c (gc) receiving only conventional physiotherapy program.

Eligibility criteria:
inclusion criteria: * patients with age range between 55 and 65 years old. * the patients were from both genders (males \&females). * patients were of duration of illness between 6 and 12 months. * the patients were scoring 1 \&1+ on modified ashworth scale (mild spasticity). * the patients were of good ability to see and hear. * consent form was obtained from all participants to approve the study and follow the commands. * all patients were scoring more than 26 on mmse. all patients were medically stable. exclusion criteria: * patients with moderate and sever spasticity. * patients with cognitive disorder due to other cause rather than spasticity. * patients with unstable medical conditions. * patients with previous or recurrent stroke. * patients with respiratory problems. * patients with shoulder dislocation or subluxation or frozen shoulder. * patients with uncontrolled hypertension, diabetes mellitus, unstable angina or heart failure.

Keywords: modified constraint induced movement therapy hemiparesis dual task training upper extremity cognitive functions
the application of indocyanine-green(icg) fluorescence imaging in hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: this study aims to evaluate the feasibility of indocyanine green (icg)-based fluorescence imaging in the detection of liver tumors. by correlating the icg fluorescence patterns with pathologically confirmed tumors , it would be possible to use fluorescence navigation system in helping promoting oncology treatment.


Eligibility criteria:
inclusion criteria: * 18 years≤ age ≤70 years * compling with the diagnosis criteria of hepatic carcinoma. * primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled. * preoperative liver function is child - pugh grade a or b. * the patients are volunteered for the study. exclusion criteria: * patients with mental illness. * patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc. * the patients refused to take part in the study. * there are other co-existed malignant tumors. * benign liver diseases. * indocyanine green allergy

Keywords: hepatocellular carcinoma indocyanine-green(icg)
effects of a low glycemic load diet on fatty liver in children

Conditions: Hepatic Steatosis

Summary: there has been a recent increase in incidence of obesity and its associated morbidities, including t2 dm, hypertension and hepatic steatosis. hepatic steatosis is a precursor to non-alcoholic steatohepatitis, cirrhosis and end-stage liver disease. the 1st reported case of pediatric hepatic steatosis was in 1980 and it is now affects 30-77% of overweight children. in addition to its association with obesity, hepatic steatosis has been associated with the metabolic syndrome, insulin resistance, and post-prandial hyperglycemia. current treatment of hepatic steatosis includes weight loss with a hypocaloric low fat diet. given the association with insulin resistance and post-prandial hyperglycemia, adult patients with hepatic steatosis that does not respond to weight loss are placed on insulin sensitizing drugs. we hypothesize that weight loss with a diet designed to decrease insulin resistance and post-prandial hyperglycemia, a low glycemic load diet, will provide a safe and effective way to decrease hepatic fat content in the pediatric population. this hypothesis will be tested with a randomized control trial comparing the effect of a low fat diet with a low glycemic load diet.


Eligibility criteria:
inclusion criteria: * bmi \>95th percentile for age and sex * weight \<300 pounds * ability to lie quietly in the mri for approximately 45 minutes * willing and able to attend all sessions. * working telephone * greater than or equal to 10% hepatic steatosis on nmr spectroscopy exclusion criteria: * any other medical condition besides obesity that may predispose to liver disease * medications that affect liver metabolism * any causes of chronic hepatitis * diabetes * inability to adhere to prescribed diets * currently on high-dose vitamins and not willing to discontinue * weight loss/gain in the past 6 months of \>10% of total body weight. * sibling of any subject who is already enrolled * any alcohol consumption

Keywords: non-alcoholic fatty liver disease steatohepatitis overweight insulin resistance
effects of epa and vitamin e on leptin, adiponectin and enzymatic antioxidants in type 2 dm

Conditions: Diabetes Mellitus

Summary: the purpose of this study is to evaluate efficacy and safety of epa(eicosapentaenoic acid)alone and with vite in diabetic patients.

randomized, double-blind, placebo-controlled, parallel-group study design after a 12weeks, subjects with type ii dm will be randomized to receive either 2000 mg pearl epa per day plus a double-blinded matching placebo (1 corn oil pearls per day) for 12 weeks or 400 mg vite pearl plus double-blinded per day plus a double-blinded matching placebo (4 corn oil pearls per day) for 12 weeks or 2000 mg pearl epa per day plus a double-blinded matching 400 mg vite pearl or placebo(4corn oil pearls per day plus 1 corn oil pearls per day )for 12 weeks.the total dose of epa pearl will be 2000 mg per day (with the epa or matching placebo corn oil doses remaining at 4 pearls per day) and the total dose of vite pearl will be 400 mg per day (with the vite or matching placebo corn oil doses remaining at 1 pearls per day).

Eligibility criteria:
inclusion criteria: * dm type ii. * antidiabetic drug therapy which cannot be stopped. * history of dm about 2-15 year. * age between 30-55 year. * no history of circulatory, thyroid, pulmonary, liver, kidney, cancer. exclusion criteria: * dm type i. * nephropathy. * retinopathy. * cancer. * thyroid disease. * renal failure. * pulmonary disease * mi. * chd. * liver disease,

Keywords: diabetes mellitus type 2 epa leptin adiponectin